SCHEMBL4313294

SCHEMBL4313294

Nc1cccc2c1CN(c1cc(C(=O)N3CCOCC3)ccc1C=Cc1n[nH]c3ccccc13)C2=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 2/20 0.45
FLT3 P36888 2/20 0.45
MAPK10 P53779 2/20 0.45
ROCK1 Q13464 2/20 0.45
BMPR1B O00238 1/20 0.45
PLK4 O00444 1/20 0.45
STK25 O00506 1/20 0.45
CIT O14578 1/20 0.45
RIOK3 O14730 1/20 0.45
CHEK1 O14757 1/20 0.45
IKBKB O14920 1/20 0.45
AURKA O14965 1/20 0.45
GAK O14976 1/20 0.45
DCLK1 O15075 1/20 0.45
CHUK O15111 1/20 0.45
MUSK O15146 1/20 0.45
EPHB6 O15197 1/20 0.45
PDPK1 O15530 1/20 0.45
MAP3K13 O43283 1/20 0.45
DAPK3 O43293 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4313289 1.00 JAK2 (0.45) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4321007 0.88 ABL1 (0.42) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4321009 0.88 ABL1 (0.42) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4321236 0.87 FLT3 (0.45) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4321233 0.87 FLT3 (0.45) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4312170 0.85 FLT3 (0.51) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4312164 0.85 FLT3 (0.51) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4309530 0.83 JAK2 (0.56) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4309523 0.83 JAK2 (0.56) JAK2FLT3MAPK10ROCK1BMPR1B
SCHEMBL4313926 0.81 KDR (0.37) JAK2FLT3MAPK10ROCK1BMPR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 JAK2 344/4885FLT3 390/4885MAPK10 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.